<DOC>
	<DOCNO>NCT01618877</DOCNO>
	<brief_summary>The part B N01362 ass pharmacokinetic profile Levetiracetam 1500 mg intravenous ( iv ) infusion repeat dose Chinese healthy volunteer .</brief_summary>
	<brief_title>A Randomized , Double-blind , Pharmacokinetics Study Assess Safety , Tolerability Levetiracetam 45 Minutes Intravenous Infusion During 4 Days Bid Dosing Chinese Healthy Volunteers</brief_title>
	<detailed_description>The study include 2 part , part A evaluate bioequivalence Levetiracetam ( LEV ) 1500 mg intravenous ( iv ) infusion compare oral tablet , part B ass pharmacokinetic profile LEV infusion repeat dose Chinese healthy volunteer .</detailed_description>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Chinese , age 1840 , weight â‰¥ 50 kg Healthy volunteer normal vital sign , good physical mental health status normal electrocardiogram laboratory test History presence system disorder capable alter absorption , metabolism elimination drug , constitute risk factor take study medication History presence drug addiction excessive use alcohol Symptomatic asymptomatic Orthostatic Hypotension screen Current smoker former smoker Heavy caffeine drinker History frequent severe headache Any drug treatment Subjects know Serum Hepatitis carrier Hepatitis B surface antigen , Hepatitis C antibody HIV positive Subjects control sodium diet Subject make blood donation comparable blood loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Keppra Levetiracetam intravenous</keyword>
	<keyword>Multiple dose</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Chinese healthy volunteer</keyword>
</DOC>